Trial Profile
Effect of olmesartan on diurnal blood pressure profile, vascular function, oxidative stress, and renal renin-angiotensin system in hypertensives with chronic kidney disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; ACE inhibitors; Antihypertensives
- Indications Hypertension
- Focus Biomarker; Therapeutic Use
- 19 Sep 2015 Status changed from recruiting to completed, as reported by University Hospital Medical Information Network - Japan record.
- 03 Nov 2008 New trial record.